Table 2.
Results From All MR Analyses for the Association of Uric Acid With Cognitive Performance and Alzheimer Disease
| Uric Acid on Cognition | β (95% CI) | P Value |
|---|---|---|
| Analysis with 28 SNPs | ||
| Fixed‐effects IVW | −0.02 (−0.04–0.01) | 0.16 |
| Weighted median | −0.03 (−0.05–−0.01) | 1.00×10−03 |
| MR‐Egger | −0.02 (−0.06–0.01) | 0.22 |
| MR‐PRESSO (outliers corrected; 3 outliers) | −0.02 (−0.04–−0.01) | 0.02 |
| MR‐PRESSO (raw) | −0.02 (−0.04–0.01) | 0.17 |
| MVMR adjusting for BMI | −0.02 (−0.04–0.01) | 0.19 |
| Analysis with 7 SNPsa | ||
| Fixed‐effects IVW | −0.03 (−0.06–0.00) | 0.08 |
| Weighted median | −0.03 (−0.05–−0.01) | 3.77×10−04 |
| MR‐Egger | −0.03 (−0.07–0.02) | 0.27 |
| MR‐PRESSO (raw; 0 outliers) | −0.03 (−0.07–0.00) | 0.09 |
| Uric Acid on Alzheimer | OR (95% CI) | P Value |
|---|---|---|
| Analysis with 28 SNPs | ||
| Fixed‐effects IVW | 1.03 (0.96–1.10) | 0.47 |
| Weighted median | 1.04 (0.95–1.14) | 0.42 |
| MR‐Egger | 1.08 (0.98–1.20) | 0.12 |
| MR‐PRESSO (raw; 0 outliers) | 1.03 (0.96–1.10) | 0.49 |
| MVMR adjusting for BMI | 1.03 (0.96–1.11) | 0.35 |
| Analysis with 7 SNPsa | ||
| Fixed‐effects IVW | 1.05 (0.93–1.17) | 0.48 |
| Weighted median | 1.05 (0.95–1.15) | 0.31 |
| MR‐Egger | 1.06 (0.90–1.25) | 0.48 |
| MR‐PRESSO (raw; 0 outliers) | 1.04 (0.93–1.17) | 0.49 |
BMI indicates body mass index; IVW, inverse variance weighted; MR‐PRESSO, Mendelian Randomization Pleiotropy Residual Sum and Outlier; MR, Mendelian randomization; MVMR, multivariable Mendelian randomization analysis; SNP, single‐nucleotide polymorphisms.
a
The 7 non‐pleiotropic SNPs that are associated with only uric acid or/and gout.